Featured Post from ChristianaCare

Researchers Discover That Cancer Stem Cell Populations in Colorectal Cancers Are Diverse, Not Uniform

Apr 4, 2023

4 min

Discovery may lead to more precise treatments for advanced colorectal cancer


Researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute have demonstrated for the first time that microRNA (miRNA) expression leads to a diversity of cancer stem cells within a colorectal cancer tumor. This diversity of cancer cells may explain why advanced colorectal cancer is difficult to treat. Study results have been in the Journal of Stem Cell Research and Therapy.


The findings broaden the understanding of how miRNA expression adds to cancer stem cell diversity and may lead to more precise anti-cancer treatments for patients with advanced colorectal cancer. The research builds on prior discoveries by scientists at the Graham Cancer Center about how cancer stem cell activity contributes to the development and spread of colorectal cancer.


“Our research shows — at least in the laboratory — that there are different subpopulations of cancer stem cells in a tumor, and they may be driving the growth of the cancer,” said Principal Investigator Bruce Boman, M.D., Ph.D., MSPH, FACP, medical director of Cancer Genetics and Stem Cell Biology at the Graham Cancer Center. “In one subpopulation of cancer stem cells, its miRNA will shut down the stem cell genes that are expressed in another subpopulation, and vice versa, within the same tumor.”


From left: ChristianaCare researchers Lynn Opdenaker, Ph.D., Brian Osmond, Bruce Boman, M.D., Ph.D., Chi Zhang, Victoria Hunsu, Caroline Facey, Ph.D. Not pictured Victoria Stark, MS.


The study focused on the composition of cancer stem cells within a colorectal cancer cell line (HT29) in the laboratory setting. Researchers evaluated the different cancer stem cell subpopulations that were identified by examining patterns of miRNA expression in each subpopulation and looking for differences. The researchers found that each of the four diverse subpopulations that were studied (ALDH, LRIG1, CD166 and LGR5) had a different miRNA expression or gene signature.


The researchers found that miRNA expression could inhibit the expression of messenger RNA (mRNA), which carries instructions from the DNA to encode specific proteins within cells. Therefore, miRNA, by controlling gene expression, dictate which proteins are contained in the stem cells. The researchers discovered the miRNA that are upregulated in certain cancer stem cell subpopulations are downregulated in other cancer stem cell subpopulations. In this way, differential miRNA expression leads to cancer stem cell heterogeneity within colorectal tumor tissue.


“It’s an early research finding and needs to be followed up with other experiments, but it has clear relevance to the clinic,” Boman said. “The question is: Can you target the miRNA to make cancer more sensitive to certain treatments? Because we know what the current anti-cancer treatments are targeting, we may be able to modulate or manipulate the cancer, so it becomes more sensitive to the treatment.”


Identification of a network of genes regulated by microRNAs in a cancer stem cell subpopulation.



For more than a decade, ChristianaCare’s researchers have contributed to the understanding of the role that cancer stem cells and miRNA expression play in the development and spread of colorectal cancer. This latest finding builds on earlier discoveries that examined a link between two cellular signaling pathways: retinoic acid (RA) signaling and wingless-related integration site (WNT) signaling, which are dysregulated by different gene mutations in colorectal tumors.


The RA signaling pathway induces growth arrest and differentiation of cancer stem cells. Notably, retinoic acid is effective against other types of cancer such as leukemia. The role of the WNT signaling pathway has an opposite effect on tumor growth. The WNT signaling pathway is activated by a mutation in the APC (adenomatous polyposis coli) gene in about 90% of cases of colorectal cancer. In APC mutant tissue, dysregulated miRNA expression may underlie an imbalance between the RA and WNT signaling, which then leads to intratumoral cancer stem cell heterogeneity. Still, this mechanism that may enable the cancer to proliferate could also provide clues on how to more effectively treat cancer.


“If you’ve got an imbalance between these two signaling pathways, then you’ve likely got a growth driver,” Boman said. “The question is: Can you suppress the WNT signaling and enhance the retinoic acid signaling?”


It may be possible to increase the sensitivity of colorectal cancer to retinoic acid-type drugs, and therapeutically shift the balance between different cancer stem cell subpopulations, thereby suppressing cancer growth. More research is needed to determine how targeted cancer therapies containing retinoic acid-type drugs may be made more effective against advanced cancer.


This research will be presented at the annual meeting of the American Association for Cancer Research in Orlando, Florida, April 14-19.


This research project was supported by a grant from the Lisa Dean Moseley Foundation.

You might also like...

Check out some other posts from ChristianaCare

1 min

ChristianaCare Nurses Inducted as American Academy of Nursing Fellows

In recognition of their extraordinary impact on the nursing profession, two ChristianaCare nurses have been named as Fellows of the American Academy of Nursing (AAN). This prestigious recognition highlights their significant contributions to nursing leadership, innovation and health care policy. Michelle Collins, DNP, APRN, CNS, ACNS-BC, NPD-BC, NEA-BC, LSSBB, currently serves as vice president of Nursing Professional Excellence at ChristianaCare. Throughout her accomplished 30-year career, Collins has played a crucial role in improving how nurses practice and learn. Her leadership was significant in achieving ChristianaCare’s third Magnet® designation, highlighting her commitment to excellence. Collins’ initiatives, including pioneering a Virtual Acute Care Nursing model and securing a $1.5 million grant for nursing technology integration, have set new standards in health care innovation. Danielle Sarik, Ph.D., APRN, CPNP-PC, is a nurse scientist consultant at ChristianaCare. Her research contributions have been integral in shaping policies that improve health care outcomes for children and families. Sarik is renowned for developing and implementing the Baby Steps model, recognized by the AAN as an Edge Runner designee. This pioneering transition of care approach addresses health equity for neonatal patients and families following discharge from the neonatal intensive care unit. “Induction into the Academy represents the highest honor in nursing,” said AAN President Linda Scott. “Earning the Fellow of the American Academy of Nursing (FAAN) credential is a significant recognition of one’s accomplishments and signifies the future impact they will make in collaboration with their colleagues in the Academy.”

3 min

‘You Can Do and Be Anything Coming From an HBCU’

A late July dinner was the finale to her second internship with ChristianaCare for Tania Paden. Her eight weeks at Christiana Hospital had left her feeling more confident in herself and excited to continue exploring direct patient care as she prepares to head back to Delaware State University in the fall. “I learned how to be more comfortable with direct patient care and communicate with the patients,” Paden said. “My favorite thing would have to be going to tour the different units and getting shadowing experiences throughout the hospital.” Paden is one of 10 Future of Health Scholarship Program recipients at ChristianaCare. Graduates from Delaware high schools attending Historically Black Colleges and Universities (HBCUs) were each awarded a $12,500 annual scholarship and a paid summer internship in 2021 each year until they graduate. The program, a partnership between ChristianaCare and the HBCU Week Foundation, is designed to help support HBCU students as they pursue degrees in health care. Teachable moments and big opportunities Paden’s enthusiasm is shared by Natalie Torres, director of Inclusion & Diversity at ChristianaCare, who oversees the scholarship program. “This experience is so much more than offering the scholarship funding,” Torres said. “It’s the time, it’s those quiet moments in-between meetings and their experiences where the teachable moments really take place. “When they come to us, we really want to lock into their lived experiences, and not only make sure they can thrive at ChristianaCare, but in life.” With these scholarships and other community-based endeavors, ChristianaCare continues to work to build a diverse workforce and represent its communities. Forbes recently listed ChristianaCare as one of America’s Best Employers for Diversity for the fourth year in a row. Although she is a young intern herself, Aniyah Barnett, a rising biochemistry junior at Hampton University, jumped at the chance to help make new caregivers feel comfortable at ChristianaCare. She played a key role welcoming medical and dental residents to campus. “My favorite project was probably the new resident orientation,” Barnett said. “I spent time getting all the new residents together, making sure they have all the information they need, and getting to meet them!” A pathway to medicine For Ashley Christopher, Esq., founder and CEO of HBCU Week Foundation, these scholarships mean a lot. Ten years ago, Christopher had a stroke that left her feeling scared and alone as she lay in hospital. Her cardiologist, a Black woman, was the only one who made her feel heard, she told the students during their summer-end dinner. With IT experiences gained at ChristianaCare, Future of Health scholar Solomon Devard is thinking about continuing on that path to become a system administrator for a big corporation. “She was the only one who made me feel safe, secure and seen during a time where I was questioning life as I knew it,” Christopher said. “You can do and be anything coming from an HBCU. This scholarship gives students who want to go to HBCUs a pathway to the field of medicine for more people who look like me to tend to the care of patients.” The HBCU Week Foundation creates opportunities through coaching and scholarships for students who want to attend HBCUs. To support these efforts, ChristianaCare committed $500,000 to providing financial and networking support, and hands-on experiences for HBCU students. “These students are energized, they’re talented, and I’m so excited for the next step,” Christopher said. “I just feel so happy to be a part of that process.”

2 min

Center for Heart & Vascular Health Recognized for Continued Excellence with American College of Cardiology HeartCARE Center Designation

For the fifth consecutive year, ChristianaCare’s Center for Heart & Vascular Health has earned the premier recognition from The American College of Cardiology (ACC) – the HeartCARE Center National Distinction of Excellence award – for its commitment to comprehensive, high quality cardiovascular care. ChristianaCare was the first hospital system in Delaware and one of only a handful in the U.S. to attain this recognition when it was first awarded in 2020 from the ACC, a nonprofit medical association representing more than 50,000 cardiovascular specialists. “We are proud to be a regional leader for cardiovascular care with the most advanced medical, surgical and minimally invasive specialty care, technology and research,” said Kirk Garratt, M.D., medical director of ChristianaCare’s Center for Heart & Vascular Health. “Congratulations to our entire team and all who collaborate seamlessly to deliver care 24/7. As a result, those living in Delaware and neighboring states can receive the highest quality cardiovascular care from the Center for Heart & Vascular Health.” Hospitals that have earned an ACC HeartCARE Center designation have met a set of criteria, including participating in at least two ACC accreditation services programs, national cardiovascular data registries and targeted quality improvement campaigns designed to close gaps in guideline-based care. In addition to being a current recipient of the HeartCARE Center designation, ChristianaCare participates in the ACC’s chest pain MI with PCI (heart attack with angioplasty) and resuscitation accreditation, cath lab accreditation and the Society of Thoracic Surgeon database. “ChristianaCare has demonstrated its commitment to providing the community with excellent heart care,” said Deepak L. Bhatt, M.D., MPH, FACC, chair of the ACC accreditation management board. “ACC accreditation services is proud to award the Center for Heart & Vascular Health with the HeartCARE Center designation.” Hospitals receiving the HeartCARE Center designation have demonstrated their commitment to consistent, high-quality cardiovascular care through comprehensive process improvement, disease and procedure-specific accreditation, professional excellence and community engagement. ChristianaCare has proven to be a forward-thinking institution with goals to advance the cause of sustainable quality improvement. The Center for Heart & Vascular Health is among the largest, most capable regional heart centers on the East Coast. It is among the few centers in the region that integrates cardiac surgery, vascular surgery, vascular interventional radiology, cardiology and interventional nephrology in a single location. Its expert clinical staff performed nearly 200,000 patient procedures last year.

View all posts
Powered by